JP7606958B2 - Ｔｒｂｃ使用の分子的評価 - Google Patents
Ｔｒｂｃ使用の分子的評価 Download PDFInfo
- Publication number
- JP7606958B2 JP7606958B2 JP2021505668A JP2021505668A JP7606958B2 JP 7606958 B2 JP7606958 B2 JP 7606958B2 JP 2021505668 A JP2021505668 A JP 2021505668A JP 2021505668 A JP2021505668 A JP 2021505668A JP 7606958 B2 JP7606958 B2 JP 7606958B2
- Authority
- JP
- Japan
- Prior art keywords
- gene
- nucleotide sequence
- cell
- region
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000011156 evaluation Methods 0.000 title description 2
- 210000004027 cell Anatomy 0.000 claims description 113
- 238000000034 method Methods 0.000 claims description 106
- 239000002773 nucleotide Substances 0.000 claims description 90
- 125000003729 nucleotide group Chemical group 0.000 claims description 90
- 101150008942 J gene Proteins 0.000 claims description 70
- 150000007523 nucleic acids Chemical class 0.000 claims description 69
- 108020004707 nucleic acids Proteins 0.000 claims description 68
- 102000039446 nucleic acids Human genes 0.000 claims description 68
- 108010087408 alpha-beta T-Cell Antigen Receptors Proteins 0.000 claims description 55
- 108090000623 proteins and genes Proteins 0.000 claims description 54
- 108020004414 DNA Proteins 0.000 claims description 41
- 230000003321 amplification Effects 0.000 claims description 32
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 32
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 claims description 31
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 claims description 31
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 claims description 31
- 238000012163 sequencing technique Methods 0.000 claims description 24
- 108700042075 T-Cell Receptor Genes Proteins 0.000 claims description 23
- 238000004458 analytical method Methods 0.000 claims description 22
- 239000003153 chemical reaction reagent Substances 0.000 claims description 13
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 11
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims description 7
- 239000002853 nucleic acid probe Substances 0.000 claims description 7
- 238000003860 storage Methods 0.000 claims description 7
- 238000001962 electrophoresis Methods 0.000 claims description 6
- 238000003499 nucleic acid array Methods 0.000 claims description 3
- 102000006707 alpha-beta T-Cell Antigen Receptors Human genes 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000000523 sample Substances 0.000 description 67
- 102100026964 M1-specific T cell receptor beta chain Human genes 0.000 description 57
- 210000001744 T-lymphocyte Anatomy 0.000 description 52
- 238000003752 polymerase chain reaction Methods 0.000 description 44
- 206010028980 Neoplasm Diseases 0.000 description 38
- 238000007481 next generation sequencing Methods 0.000 description 35
- 101000662909 Homo sapiens T cell receptor beta constant 1 Proteins 0.000 description 33
- 102100037272 T cell receptor beta constant 1 Human genes 0.000 description 33
- 230000008707 rearrangement Effects 0.000 description 30
- 230000009258 tissue cross reactivity Effects 0.000 description 27
- 101000662902 Homo sapiens T cell receptor beta constant 2 Proteins 0.000 description 25
- 102100037298 T cell receptor beta constant 2 Human genes 0.000 description 25
- 230000008901 benefit Effects 0.000 description 23
- 239000000047 product Substances 0.000 description 22
- 238000003556 assay Methods 0.000 description 21
- 238000013459 approach Methods 0.000 description 20
- 238000001574 biopsy Methods 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 16
- 101000763322 Homo sapiens M1-specific T cell receptor beta chain Proteins 0.000 description 14
- 101000763321 Homo sapiens T cell receptor beta chain MC.7.G5 Proteins 0.000 description 14
- 208000007660 Residual Neoplasm Diseases 0.000 description 13
- 108091008874 T cell receptors Proteins 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 12
- 206010042971 T-cell lymphoma Diseases 0.000 description 9
- 238000004590 computer program Methods 0.000 description 9
- 238000003364 immunohistochemistry Methods 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 8
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 8
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 8
- 108060003951 Immunoglobulin Proteins 0.000 description 7
- 238000013461 design Methods 0.000 description 7
- 102000018358 immunoglobulin Human genes 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- 230000036210 malignancy Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 108091093088 Amplicon Proteins 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 230000002998 immunogenetic effect Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000005215 recombination Methods 0.000 description 5
- 230000006798 recombination Effects 0.000 description 5
- 230000003044 adaptive effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940072221 immunoglobulins Drugs 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- BSDCIRGNJKZPFV-GWOFURMSSA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-(2,5,6-trichlorobenzimidazol-1-yl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=CC(Cl)=C(Cl)C=C2N=C1Cl BSDCIRGNJKZPFV-GWOFURMSSA-N 0.000 description 3
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 102000006943 Uracil-DNA Glycosidase Human genes 0.000 description 3
- 108010072685 Uracil-DNA Glycosidase Proteins 0.000 description 3
- 101150117115 V gene Proteins 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000005304 joining Methods 0.000 description 3
- 238000007403 mPCR Methods 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 210000002741 palatine tonsil Anatomy 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- GUAHPAJOXVYFON-ZETCQYMHSA-N (8S)-8-amino-7-oxononanoic acid zwitterion Chemical compound C[C@H](N)C(=O)CCCCCC(O)=O GUAHPAJOXVYFON-ZETCQYMHSA-N 0.000 description 2
- 238000007400 DNA extraction Methods 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 101000658404 Homo sapiens T cell receptor beta variable 29-1 Proteins 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 101150006978 J1 gene Proteins 0.000 description 2
- 101150061944 J2 gene Proteins 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 102100034879 T cell receptor beta variable 29-1 Human genes 0.000 description 2
- 241000656145 Thyrsites atun Species 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 238000002679 ablation Methods 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 210000005170 neoplastic cell Anatomy 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000002864 sequence alignment Methods 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 238000009966 trimming Methods 0.000 description 2
- 101100519158 Arabidopsis thaliana PCR2 gene Proteins 0.000 description 1
- 241000222400 Athelia Species 0.000 description 1
- 101150111062 C gene Proteins 0.000 description 1
- 101150061009 C1 gene Proteins 0.000 description 1
- 101150003288 C2 gene Proteins 0.000 description 1
- 101100180402 Caenorhabditis elegans jun-1 gene Proteins 0.000 description 1
- -1 DNA Chemical class 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 108091027305 Heteroduplex Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000645337 Homo sapiens T cell receptor beta joining 1-1 Proteins 0.000 description 1
- 101000645349 Homo sapiens T cell receptor beta joining 1-6 Proteins 0.000 description 1
- 101000645350 Homo sapiens T cell receptor beta joining 2-1 Proteins 0.000 description 1
- 101000763986 Homo sapiens T cell receptor beta joining 2-7 Proteins 0.000 description 1
- 101000679306 Homo sapiens T cell receptor gamma constant 1 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001289721 Lethe Species 0.000 description 1
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 101150102573 PCR1 gene Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 102100026269 T cell receptor beta joining 1-1 Human genes 0.000 description 1
- 102100026270 T cell receptor beta joining 1-6 Human genes 0.000 description 1
- 102100026271 T cell receptor beta joining 2-1 Human genes 0.000 description 1
- 102100026919 T cell receptor beta joining 2-7 Human genes 0.000 description 1
- 102100022590 T cell receptor gamma constant 1 Human genes 0.000 description 1
- 108700042077 T-Cell Receptor beta Genes Proteins 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 102000011778 gamma-delta T-Cell Antigen Receptors Human genes 0.000 description 1
- 108010062214 gamma-delta T-Cell Antigen Receptors Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000013388 immunohistochemistry analysis Methods 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000012205 qualitative assay Methods 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 231100000004 severe toxicity Toxicity 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023211088A JP2024023671A (ja) | 2018-08-03 | 2023-12-14 | Ｔｒｂｃ使用の分子的評価 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1812650.8A GB201812650D0 (en) | 2018-08-03 | 2018-08-03 | Molecular assessment of TRBC usage |
| GB1812650.8 | 2018-08-03 | ||
| PCT/GB2019/052011 WO2020025928A1 (en) | 2018-08-03 | 2019-07-18 | Molecular assessment of trbc usage |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023211088A Division JP2024023671A (ja) | 2018-08-03 | 2023-12-14 | Ｔｒｂｃ使用の分子的評価 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021532792A JP2021532792A (ja) | 2021-12-02 |
| JP2021532792A5 JP2021532792A5 (https=) | 2022-05-30 |
| JP7606958B2 true JP7606958B2 (ja) | 2024-12-26 |
Family
ID=63518375
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021505668A Active JP7606958B2 (ja) | 2018-08-03 | 2019-07-18 | Ｔｒｂｃ使用の分子的評価 |
| JP2023211088A Pending JP2024023671A (ja) | 2018-08-03 | 2023-12-14 | Ｔｒｂｃ使用の分子的評価 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023211088A Pending JP2024023671A (ja) | 2018-08-03 | 2023-12-14 | Ｔｒｂｃ使用の分子的評価 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12241124B2 (https=) |
| EP (1) | EP3830297A1 (https=) |
| JP (2) | JP7606958B2 (https=) |
| CN (1) | CN112534065B (https=) |
| AU (1) | AU2019312877B2 (https=) |
| CA (1) | CA3108000A1 (https=) |
| GB (1) | GB201812650D0 (https=) |
| WO (1) | WO2020025928A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11385233B2 (en) | 2015-03-05 | 2022-07-12 | Autolus Limited | Methods of depleting malignant T-cells |
| US11982673B2 (en) | 2014-03-05 | 2024-05-14 | Autolus Limited | Methods |
| GB201709203D0 (en) | 2017-06-09 | 2017-07-26 | Autolus Ltd | Antigen-binding domain |
| US12247060B2 (en) | 2018-01-09 | 2025-03-11 | Marengo Therapeutics, Inc. | Calreticulin binding constructs and engineered T cells for the treatment of diseases |
| EP3765517A1 (en) | 2018-03-14 | 2021-01-20 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| CA3105448A1 (en) | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| GB201817172D0 (en) | 2018-10-22 | 2018-12-05 | Autolus Ltd | Antibody |
| GB201817822D0 (en) | 2018-10-31 | 2018-12-19 | Autolus Ltd | Binding domain |
| GB2599228B (en) | 2019-02-21 | 2024-02-07 | Marengo Therapeutics Inc | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
| CN119039441A (zh) | 2019-02-21 | 2024-11-29 | 马伦戈治疗公司 | 与nkp30结合的抗体分子及其用途 |
| AU2020416273A1 (en) | 2020-01-03 | 2022-07-28 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
| WO2023236189A1 (zh) * | 2022-06-10 | 2023-12-14 | 刘宗霖 | 利用非完整重组的t细胞受体核苷酸序列诊断t细胞淋巴瘤的方法及试剂盒 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103205420A (zh) | 2012-01-13 | 2013-07-17 | 深圳华大基因科技有限公司 | 用于扩增T细胞受体β链CDR3编码序列的引物组合物及其用途 |
| JP2017510257A (ja) | 2014-03-05 | 2017-04-13 | ユーシーエル ビジネス ピーエルシー | Ｔ細胞受容体ベータ定常領域に対する抗原結合ドメインを有するキメラ抗原抗体（ｃａｒ） |
| US20180201991A1 (en) | 2016-12-09 | 2018-07-19 | Regeneron Pharmaceuticals, Inc. | Systems and Methods for Sequencing T Cell Receptors and Uses Thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102443624B (zh) * | 2010-10-11 | 2014-12-10 | 遵义医学院 | 一种高通量同时测序多样本cdr3受体库的方法 |
| US11385233B2 (en) | 2015-03-05 | 2022-07-12 | Autolus Limited | Methods of depleting malignant T-cells |
| WO2016051205A1 (en) | 2014-10-03 | 2016-04-07 | Isis Innovation Limited | Analysis of t-cell monotypia |
| EP3211003A1 (en) * | 2016-02-24 | 2017-08-30 | Institut Pasteur | T cell receptors from the hiv-specific repertoire, means for their production and therapeutic uses thereof |
| GB201709203D0 (en) | 2017-06-09 | 2017-07-26 | Autolus Ltd | Antigen-binding domain |
| GB201800298D0 (en) | 2018-01-09 | 2018-02-21 | Autolus Ltd | Method |
| GB201817172D0 (en) | 2018-10-22 | 2018-12-05 | Autolus Ltd | Antibody |
| GB201817822D0 (en) | 2018-10-31 | 2018-12-19 | Autolus Ltd | Binding domain |
-
2018
- 2018-08-03 GB GBGB1812650.8A patent/GB201812650D0/en not_active Ceased
-
2019
- 2019-07-18 US US17/264,217 patent/US12241124B2/en active Active
- 2019-07-18 CA CA3108000A patent/CA3108000A1/en active Pending
- 2019-07-18 JP JP2021505668A patent/JP7606958B2/ja active Active
- 2019-07-18 EP EP19745224.6A patent/EP3830297A1/en active Pending
- 2019-07-18 CN CN201980051847.3A patent/CN112534065B/zh active Active
- 2019-07-18 AU AU2019312877A patent/AU2019312877B2/en active Active
- 2019-07-18 WO PCT/GB2019/052011 patent/WO2020025928A1/en not_active Ceased
-
2023
- 2023-12-14 JP JP2023211088A patent/JP2024023671A/ja active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103205420A (zh) | 2012-01-13 | 2013-07-17 | 深圳华大基因科技有限公司 | 用于扩增T细胞受体β链CDR3编码序列的引物组合物及其用途 |
| JP2017510257A (ja) | 2014-03-05 | 2017-04-13 | ユーシーエル ビジネス ピーエルシー | Ｔ細胞受容体ベータ定常領域に対する抗原結合ドメインを有するキメラ抗原抗体（ｃａｒ） |
| US20180201991A1 (en) | 2016-12-09 | 2018-07-19 | Regeneron Pharmaceuticals, Inc. | Systems and Methods for Sequencing T Cell Receptors and Uses Thereof |
Non-Patent Citations (1)
| Title |
|---|
| 暮らしっく不動産[online]，MacBook Pro (13-inch, Mid 2012)のメモリ交換 CPUとメモリとHD，公開日：2017 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3108000A1 (en) | 2020-02-06 |
| US12241124B2 (en) | 2025-03-04 |
| JP2024023671A (ja) | 2024-02-21 |
| JP2021532792A (ja) | 2021-12-02 |
| CN112534065B (zh) | 2025-08-26 |
| CN112534065A (zh) | 2021-03-19 |
| US20220010377A1 (en) | 2022-01-13 |
| WO2020025928A1 (en) | 2020-02-06 |
| EP3830297A1 (en) | 2021-06-09 |
| GB201812650D0 (en) | 2018-09-19 |
| AU2019312877B2 (en) | 2025-12-18 |
| AU2019312877A1 (en) | 2021-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7606958B2 (ja) | Ｔｒｂｃ使用の分子的評価 | |
| US20240401140A1 (en) | Methods and processes for non-invasive assessment of genetic variations | |
| JP5662155B2 (ja) | Ｖ（ｄ）ｊ組み合わせ多様性を研究する方法 | |
| KR20210052511A (ko) | 무세포 dna에서의 미세부수체 불안정성 검출 | |
| JPH03504325A (ja) | Ｈｌａ ｄｐタイプ分け方法 | |
| AU2009244634A1 (en) | Method for evaluating and comparing immunorepertoires | |
| KR20080025040A (ko) | 일광 노출, 전립선암 및 다른 암의 검출용 진단 도구로서미토콘드리아 돌연변이 및 전위 | |
| CN105164277B (zh) | 用于评估免疫组库的方法 | |
| JP2023515270A (ja) | Ｔｃｒ／ｂｃｒプロファイリング | |
| CN108368554B (zh) | 弥漫性大b细胞淋巴瘤(dlbcl)亚型分型的方法 | |
| US20100086918A1 (en) | Methods for High Sensitivity Detection of Genetic Polymorphisms | |
| TW201936921A (zh) | 次世代定序儀用引子以及其製造方法、使用次世代定序儀用引子之ｄｎａ庫以及其製造方法，及使用ｄｎａ庫之基因體ｄｎａ解析方法 | |
| JP2026062846A (ja) | 核酸配列分析方法 | |
| Rodriguez et al. | Antibody repertoire gene usage is explained by common genetic variants in the immunoglobulin heavy chain locus | |
| Gan | The Quantification of Antibody Elements and Receptors subunit expression using qPCR: Designing of VH, VL, CH, CL, FcR subunits primers for a more holistic view of the immune system | |
| Nichols | The Application of Molecular Genetic Techniques in Forensic Science | |
| WO2024118500A2 (en) | Methods for detecting and treating ovarian cancer | |
| Brisco | Quantifying Residual Leukemia by “Clone-Specific” Polymerase Chain Reaction | |
| WO2021202861A1 (en) | Method of characterisation | |
| Hiyoshi | Studies on GeneScan analysis of immunoglobulin and T cell receptor genes in canine lymphoproliferative diseases | |
| US20100291563A1 (en) | Assessing tissue rejection | |
| Braziel et al. | B-cell lymphomas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220520 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220520 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230616 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230915 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20231115 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231214 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20240202 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240603 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20240805 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20241022 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20241121 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20241216 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7606958 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |